- Home
- LPL vs KNSA Comparison
LPL vs KNSA Comparison
Compare LPL & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPL | KNSA |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | South Korea | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | 2004 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LPL | KNSA |
|---|---|---|
| Price | $4.52 | $46.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $55.29 |
| AVG Volume (30 Days) | ★ 2.2M | 565.9K |
| Earning Date | 05-14-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $1.04 | $38.01 |
| Revenue Next Year | $3.00 | $17.42 |
| P/E Ratio | ★ $25.64 | $63.27 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $2.72 | $19.42 |
| 52 Week High | $5.67 | $50.03 |
Technical Indicators
Market Signals| Indicator | LPL | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 60.45 | 51.17 |
| Support Level | $4.16 | $39.96 |
| Resistance Level | $5.07 | $48.14 |
| Average True Range (ATR) | 0.20 | 1.83 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 94.41 | 45.20 |
Price Performance
Historical ComparisonAbout LPL LG Display Co Ltd AMERICAN DEPOSITORY SHARES
LG Display Co Ltd is a South Korea-based company that is principally engaged in developing, manufacturing, and selling TFT-LCD and OLED display panels. The company's products consist of panels for notebook computers, monitors, televisions, smartphones, tablets, and others. The company conducts direct sales through overseas subsidiaries in several countries, including the United States, Germany, Japan, Taiwan, China, and Singapore. These subsidiaries conduct sales activities and offer technical support to clients. The company generates the majority of its revenue from overseas markets, with the rest from South Korea.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.